Literature DB >> 1316670

Rapid in vivo induction of HIV-specific CD8+ cytotoxic T lymphocytes by a 15-amino acid unmodified free peptide from the immunodominant V3-loop of GP120.

K J Sastry1, P N Nehete, S Venkatnarayanan, J Morkowski, C D Platsoucas, R B Arlinghaus.   

Abstract

Efforts to generate a vaccine to prevent infection by human immunodeficiency virus (HIV) have focused on inducing neutralizing antibodies. However, cytotoxic T-lymphocyte (CTL) responses are a major immune defense mechanism required for recovery from many different virus infections. Since CTL epitopes can be defined by short synthetic peptides, we searched for HIV peptides that elicit a viral-specific CTL response in mice. We have developed a new method for screening CTL-inducing peptides involving a single injection into the footpad of mice to prime CTLs in the draining popliteal lymph node of mice within 10 days. Our results demonstrate that a 15-amino acid peptide (aa 315-329) derived from the V3 loop of HIV gp120 caused a rapid induction of peptide-specific and gp160-specific CD8-positive CTLs. Lysis of targets is specific since cells preincubated with unrelated peptides are resistant to lysis as are cells of a different MHC haplotype pretreated with the cognate peptide. Pretreatment of restimulated node cells with complement plus anti-CD8 but not anti-CD4 removed the lytic activity. We also successfully induced in vivo CTL activity with unmodified synthetic peptides from the influenza and Sendai virus nucleoproteins, indicating general applicability of our method for rapid screening of CTL epitopes. Because HIV replication has been reported by several labs to occur mainly in lymph nodes of infected patients, the rapid induction of HIV-specific CTLs in proximal lymph nodes by unmodified peptides emphasizes the physiological significance of our findings toward vaccine and therapeutic approaches.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1316670     DOI: 10.1016/0042-6822(92)90504-i

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  8 in total

1.  Impairment of antigen-specific cellular immune responses under simulated microgravity conditions.

Authors:  K J Sastry; P N Nehete; C A Savary
Journal:  In Vitro Cell Dev Biol Anim       Date:  2001-04       Impact factor: 2.416

2.  Cross-reactive T-cell proliferative responses to V3 peptides corresponding to different geographical HIV-1 isolates in HIV-seropositive individuals.

Authors:  P N Nehete; P C Johnson; S J Schapiro; R B Arlinghaus; K J Sastry
Journal:  J Clin Immunol       Date:  1996-03       Impact factor: 8.317

3.  Intranasal but not intravenous delivery of the adjuvant α-galactosylceramide permits repeated stimulation of natural killer T cells in the lung.

Authors:  Amy N Courtney; Prakash Thapa; Shailbala Singh; Ameerah M Wishahy; Dapeng Zhou; Jagannadha Sastry
Journal:  Eur J Immunol       Date:  2011-09-19       Impact factor: 5.532

4.  Animal model of mucosally transmitted human immunodeficiency virus type 1 disease: intravaginal and oral deposition of simian/human immunodeficiency virus in macaques results in systemic infection, elimination of CD4+ T cells, and AIDS.

Authors:  S V Joag; I Adany; Z Li; L Foresman; D M Pinson; C Wang; E B Stephens; R Raghavan; O Narayan
Journal:  J Virol       Date:  1997-05       Impact factor: 5.103

5.  Intranasal immunization with synthetic peptides corresponding to the E6 and E7 oncoproteins of human papillomavirus type 16 induces systemic and mucosal cellular immune responses and tumor protection.

Authors:  Pallavi R Manuri; Bharti Nehete; Pramod N Nehete; Rose Reisenauer; Seth Wardell; Amy N Courtney; Ratish Gambhira; Dakshyani Lomada; Ashok K Chopra; K Jagannadha Sastry
Journal:  Vaccine       Date:  2007-01-24       Impact factor: 3.641

6.  Rapid screening for Mamu-A1-positive rhesus macaques using a SIVmac Gag peptide-specific cytotoxic T-lymphocyte assay.

Authors:  T Vogel; S Norley; B Beer; R Kurth
Journal:  Immunology       Date:  1995-03       Impact factor: 7.397

7.  Inhibition of human immunodeficiency virus type 1 infection and syncytium formation in human cells by V3 loop synthetic peptides from gp120.

Authors:  P N Nehete; R B Arlinghaus; K J Sastry
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens.

Authors:  Amy N Courtney; Pramod N Nehete; Bharti P Nehete; Prakash Thapa; Dapeng Zhou; K Jagannadha Sastry
Journal:  Vaccine       Date:  2009-02-05       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.